期刊文献+

Intermedin/adrenomedullin 2及其受体在慢性低氧性肺动脉高压大鼠右心室的表达变化 被引量:17

Changes of intermedin/adrenomedullin 2 and its receptors in the right ventricle of rats with chronic hypoxic pulmonary hypertension
下载PDF
导出
摘要 本研究探讨了新发现的小分子生物活性肽intermedin/adrenomedullin 2(IMD/ADM2)及其受体在慢性低氧性肺动脉高压大鼠右心室中的变化和可能作用。用放射免疫分析法测定正常对照组和常压低氧4周组Sprague-Dawley大鼠血浆、右心室匀浆IMD/ADM2和肾上腺髓质素(adrenomednllin,ADM)蛋白水平;逆转录-多聚酶链反应法测定右心室IMD/ADM2、ADM及受体:降钙素受体样受体(calcitonin receptor-like receptor,CRLR)、受体活性修饰蛋白1,2,3(receptor activity modifying protein 1,2,3,RAMP1,RAMP2,RAMP3)mRNA表达。结果显示:低氧组平均肺动脉压、右心室与左心室加室间隔重量比[RV/(LV+S)]显著高于对照组(均P<0.01);低氧组血浆和右心室组织匀浆ADM水平比对照组分别高1.26倍和1.68倍(P<0.01),IMD/ADM2水平则较对照组分别高0.90倍和1.19倍(P<0.01);与对照组相比,低氧组右心室IMD/ADM2、ADM mRNA表达均上调(P<0.01),RAMP2 mRNA表达增强(P<0.05),而两组间CRLR、RAMP1、RAMP3 mRNA的表达水平无显著性差异。结果表明,慢性低氧性肺动脉高压大鼠IMD/ADM2表达水平升高。 The purpose of the present study was to explore the expression changes of intermedin/adrenomedullin 2 (IMD/ADM2), a novel small molecular bioactive peptide, and its receptors, calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMP1, RAMP2, RAMP3) in the right ventricle of rats with chronic hypoxia-induced pulmonary hypertension. Twenty male Sprague-Dawley rats were randomly divided into 4-week hypoxia group and normal control group (each n= 10). The rats in hypoxia group were placed in an isobaric hypoxic chamber, in which O2 content was maintained at 9%-11% by delivering N2, and CO2 content was maintained at 〈3% for 4 weeks (8 h/d, 6 d/week). The rats in the control group were housed in room air. The protein levels of IMD/ ADM2 and adrenomedullin (ADM) in blood plasma and right ventricutar tissue were measured by radioimmunoassay. The mRNA expressions of IMD/ADM2, ADM and their receptors CRLR, RAMP1, RAMP2, RAMP3 in right ventricular tissue were determined by reverse transcription-polymerase chain reaction (RT-PCR). The results showed that the ratio of right ventricle weight to left ventricle plus septum weight [RV/(LV+S)] and mean pulmonary medal pressure (mPAP) were higher in hypoxia group than those in the control group (all P〈0.01), suggesting that the rat model of pulmonary hypertension was successfully established. However, the mean carotid arterial pressure (mCAP) between the two groups had no significant difference. Compared with that in the control group, ADM contents in plasma and right ventricular tissue in hypoxia group increased by 1.26 and 1.68 folds (all P〈0.01), respectively. Likewise,IMD/ADM2 contents in blood plasma and right ventricular tissue in hypoxia group increased by 0.90 and 1.19 folds (P〈0.01), respectively, compared with that in the control group. The data of RT-PCR showed that mRNA levels of ADM, IMD/ADM2 and RAMP2 in hypoxia group increased by 155.1% (P〈0.01), 80.9% (P〈0.01) and 52.9% (P〈0.05), respectively, compared with those in the control group. There were no significant differences in mRNA expressions of CRLR, RAMP1 and RAMP3 between the two groups (all P〉0.05). Taken together, the results show that the level of IMD/ADM2 increases in the rats with chronic hypoxia-induced pulmonary hypertension.
出处 《生理学报》 CAS CSCD 北大核心 2007年第2期210-214,共5页 Acta Physiologica Sinica
基金 This work was supported by the Natural Science Foundation of Zhejiang Province (No. Y206464).
关键词 肾上腺髓质素 INTERMEDIN 受体 低氧:高血压 肺性 adrenomeduUin intermedin receptor hypoxia hypertension, pulmonary
  • 相关文献

参考文献13

  • 1Kitamura K,Kangawa K,Kawamoto M,Ichiki Y,Nakamura S,Matsuo H,Eto T.Adrenomedullin:a novel hypotensive peptide isolated from human pheochromocytoma.Biochem Biophys Res Commun 1993; 192(2):553-560.
  • 2Beltowski J,Jamroz A.Adrenomedullin-what do we know 10 years since its discovery? Pol J Pharmacol 2004; 56(1):5-27.
  • 3Nagaya N,Nishikimi T,Uematsu M,Satoh T,Oya H,Kyotani S,Sakamaki F,Ueno K,Nakanishi N,Miyatake K,Kangawa K.Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension.Heart 2000; 84(6):653-658.
  • 4齐永芬,卜定方,石彦荣,李菊香,庞永正,唐朝枢.自发性高血压大鼠和Wistar-Kyoto大鼠心血管组织肾上腺髓质素和肾上腺髓质素原N-末端20肽的水平(英文)[J].生理学报,2003,55(3):260-264. 被引量:1
  • 5Takei Y,Hyodo S,Katafuchi T,Minamino N.Novel fishderived adrenomedullin in mammals:structure and possible function.Peptides 2004; 25(10):1643-1656.
  • 6Takei Y,Inoue K,Ogoshi M,Kawahara T,Bannai H,Miyano S.Identification of novel adrenomedullin in mammals:a potent cardiovascular and renal regulator.FEBS Lett 2004; 556(1-3):53-58.
  • 7Roh J,Chang CL,Bhalla A,Klein C,Hsu SY.Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes.J Biol Chem 2004; 279(8):7264-7274.
  • 8Pan CS,Yang JH,Cai DY,Zhao J,Gerns H,Yang J,Chang JK,Tang CS,Qi YF.Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2.Peptides 2005;26(9):1640-1646.
  • 9Burak Kandilci H,Gumusel B,Wasserman A,Witriol N,Lippton H.Intermedin/adrenomedullin-2 dilates the rat pulmonary vascular bed:Dependence on CGRP receptors and nitric oxide release.Peptides 2006; 27(6):1390-1396.
  • 10Nakanishi K,Osada H,Uenoyama M,Kanazawa F,Ohrui N,Masaki Y,Hayashi T,Kanatani Y,Ikeda T,Kawai T.Expressions of adrenomedullin mRNA and protein in rats with hypobaric hypoxia-induced pulmonary hypertension.Am J Physiol Heart Cir Physiol 2004; 286(6):H2159-H2168.

二级参考文献21

  • 1Etoh T, Kato J, Takenaga M, Imamura T, Kitamura K,Kirwaya Y, Eto T. Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels. Clin Cardiol 1999 ;22:113 - 117.
  • 2Shimosawa T, Kanozawa K, Nagasawa R, Mitarai T, Isoda K, Takahashi K, Ando K, Tozawa Y, Nagase M, Sasaki N, Fujita M, Takano K, Iiri T, Fujita T. Adrenomedullin amidation enzyme activities in hypertensive patients. Hypertens Res 2000 , 23 :167 - 171.
  • 3Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is devdopmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 1998;273 (28) :17787 -17792.
  • 4Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju K-H,Minamino N, Kangawa K, Ishikawa T, Fukuda M,Akomoto Y, Kawakami H, Imai T, Morita H, Yazaki Y,Nagai R, Hirata Y, Kurihara H. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001 ; 104:1964 - 1971.
  • 5Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling,and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000;36(6) :995 - 1001.
  • 6Gumusel B, Chang JK, Hyman A, Lippton H. Adrenotensin: an ADM gene product with the opposite effects of ADM. Life Sci 1995;57(8) :PL 87 -90.
  • 7Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.Biochem Biophys Res Commun 1993;192(2): 552- 560.
  • 8Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomodullin. Biochem Biophys Res Commun 1993 ; 194 ( 2 ) : 720 - 725.
  • 9Samson WK. Proadrenomedullin-derived peptides. Front Neuroendocrin 1998 ; 19 : 100 - 127.
  • 10Masada K, Nagayama T, Hosokawa A, Yoshida M, Suzuki-Kusaba M, Hisa H, Kimura T, Satoh S. Effects of adrenomedullin and PAMP on adrenal catecholamine release in dogs. Am J Phys 1999;276:Rl118 -Rl124.

同被引文献122

引证文献17

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部